BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlaxoSmithKline (GSK)'s Malaria Vaccine Ineffective Over Time


3/21/2013 8:27:56 AM

Optimism over the new malaria vaccine being tested in Africa could be set to fall after results suggested its effect could reduce over time and that it disappears fastest in children who are most exposed to malarial mosquito bites. Scientists point out that they will need to see the full results, from large-scale trials of thousands of children, before they really know how useful the vaccine – developed by GlaxoSmithKline and known only as RTS,S – will be. But the tests follow a string of disappointing results, which have clearly shown how difficult it is to make a vaccine to protect against the disease, which kills more than 650,000 children, most of them very young, a year. Last year a large-scale phase III trial showed that the vaccine saved only a third of babies aged six to 12 weeks old from falling ill. This is the age group that the vaccine is intended for, but the protection was lower than that which appeared in older children. "The efficacy came back lower than we had hoped, but developing a vaccine against a parasite is a very hard thing to do," said Bill Gates, co-founder of the Bill & Melinda Gates Foundation and one of the research funders, at the time. The latest findings, published in the New England Journal of Medicine, come from a smaller phase II trial that began in 2009 and was designed to assess safety and efficacy ahead of the large-scale phase III trials. It involved 447 children in Kilifi, Kenya, 320 of whom were followed up for four years.

Read at Guardian
Read at Reuters
Read at New Vision
Read at BusinessWeek
Read at Triangle Business Journal

   
Malaria

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES